Is MENS or MIRM more undervalued in 2026?

CirclFi compares Jyong Biotech Ltd. (MENS) and Mirum Pharmaceuticals, Inc. (MIRM) using 13 institutional-grade valuation models. MENS has a Quality of Company score of 2.3/10 while MIRM scores 7.1/10.

Which is a better buy — MENS or MIRM?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do MENS and MIRM valuations compare?

MENS at $2.25 and MIRM at $99.60 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

MENS vs MIRM Valuation Comparison 2026 — Intrinsic Value Analysis

MENS

Biotechnology

Jyong Biotech Ltd.

Quality

2.3

out of 10

Value Trap

—

Price

$2.25

Last close

Models

9/13

Active

MIRM

Biotechnology

Mirum Pharmaceuticals, Inc.

Quality

7.1

out of 10

Value Trap

SAFE

Price

$99.60

Last close

Models

13/13

Active

Model-by-Model Comparison

Model	Type	MENS Fair Value	MENS Upside	MIRM Fair Value	MIRM Upside
Bayesian DCF	Intrinsic	$0.60	-73.5%	$15.18	-84.8%
Earnings Power Value	Intrinsic	—	—	$48.67	-46.8%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$0.17	-92.1%	$15.18	-84.8%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for MENS vs MIRM — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

MENS vs MIRM — Which Stock Is More Undervalued?

MIRM scores higher with a 7.1/10 quality rating vs MENS's 2.3/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Jyong Biotech Ltd. (MENS) and Mirum Pharmaceuticals, Inc. (MIRM) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

MENS currently trades at $2.25 with a QOC of 2.3/10, while MIRM trades at $99.60 with a QOC of 7.1/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).